Quest Diagnostics (DGX) Downgraded by Deutsche Bank
The firm currently has $108.00 price target on the medical research company's stock. A number of other equities analysts also recently commented on the company.
from Biotech News
The firm currently has $108.00 price target on the medical research company's stock. A number of other equities analysts also recently commented on the company.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments